The prognostic value of semiquantitative nuclear grading in endometrial carcinomas.

Abstract:

:The objective of this study was to evaluate the prognostic value of a convenient nuclear grading system based on only the proportion of nuclei measuring more than 10 microm in length at the shortest axis in endometrial carcinomas. Of the 235 cases reviewed, 9 serous and 5 clear cell adenocarcinomas and 2 small cell carcinomas were eliminated, resulting in a study population of 219 cases of endometrial adenocarcinoma. The architectural grade was determined by the FIGO system. The criteria for nuclear grade were as follows: grade 1, no nucleus measuring more than 10 microm in length at the shortest axis; grade 2, nuclei measuring more than 10 microm in length at the shortest axis seen in percentages ranging between 0 and 10% of tumor cells in active areas; and grade 3, more than 10% of tumor cells in active areas with nuclei measuring more than 10 microm in length at the shortest axis. The criteria for combined grades were as follows: the tumors were graded according to the architectural grade, but high-grade nuclear abnormalities increased the grade by one for architectural grade 1 and 2 tumors. The cumulative 10-year survival rates for architectural grades 1, 2, and 3 were 92.4, 82.6, and 65.2%, respectively (chi2 = 17.9, P = 0.001). The survival rates for nuclear grades 1, 2, and 3 were 96.2, 76.1, and 70.1%, respectively (chi2 = 21.6, P < 0.001), while for combined grades 1, 2, and 3 the survival rates were 98.3, 83.2, and 65.2%, respectively (chi2 = 26.9, P < 0.001). Even when the cases were limited to the 147 stage I endometrial carcinomas examined, the prognostic value of the combined grading system was still found to be superior to that of the architectural grading system. Our observations therefore supported the FIGO recommendation for nuclear grade not only in stage I endometrial carcinomas, but also in all stages of endometrial carcinomas.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Hachisuga T,Kawarabayashi T,Iwasaka T,Sugimori H,Kamura T,Tsuneyoshi M

doi

10.1006/gyno.1997.4631

subject

Has Abstract

pub_date

1997-04-01 00:00:00

pages

115-20

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(97)94631-X

journal_volume

65

pub_type

杂志文章
  • Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.

    abstract:OBJECTIVE:The objective of this study is to examine the outcomes of combined chemotherapy using methotrexate and dactinomycin in the management of women with low-risk gestational trophoblastic neoplasia (GTN). The primary outcome is the total number of cycles of chemotherapy required to achieve a normal level of human ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.10.036

    authors: Eiriksson L,Wells T,Steed H,Schepansky A,Capstick V,Hoskins P,Pike J,Swenerton K

    更新日期:2012-03-01 00:00:00

  • Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

    abstract:OBJECTIVE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediates apoptosis via binding to death receptors and enhances the anti-tumor effect of conventional cancer therapies. We evaluated the efficacy of TRA-8, an agonistic antibody to DR5, combined with docetaxel and carboplatin in vitro in an intrap...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.11.046

    authors: Bevis KS,McNally LR,Sellers JC,Della Manna D,Londoño Joshi A,Amm H,Straughn JM Jr,Buchsbaum DJ

    更新日期:2011-04-01 00:00:00

  • Stage IV ovarian cancer: impact of surgical debulking.

    abstract:OBJECTIVE:To evaluate the influence of surgical debulking performed on patients with Stage IV ovarian cancer and to determine prognostic factors which identify pts who may benefit from aggressive initial surgical debulking. METHODS:A retrospective chart review was conducted (1/1/87-12/31/93). Eligible patients include...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.4550

    authors: Curtin JP,Malik R,Venkatraman ES,Barakat RR,Hoskins WJ

    更新日期:1997-01-01 00:00:00

  • Role of an early second-look laparotomy in ovarian cancer.

    abstract::Of a group of 68 patients treated with standard polychemotherapy (CAP-5), 52 were evaluated by an early second-look laparotomy, preferably after three cycles of treatment. Of 21 patients with initial tumor residuals smaller than 2 cm, only 5 had residual tumor, and of 31 patients with tumor larger than 2 cm, 27 had re...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90055-3

    authors: van Lith JM,Bouma J,Aalders JG,Boonstra H,Sleijfer DT,Willemse PH

    更新日期:1989-11-01 00:00:00

  • Syndrome of inappropriate antidiuresis in ovarian serous carcinoma with neuroendocrine differentiation.

    abstract::A 58-year-old postmenopausal woman with primary ovarian serous carcinoma presented with the syndrome of inappropriate antidiuresis (SIAD). Preoperative workup showed serum sodium level of 110 mEq/liter and antidiuretic hormone level of 3.3 pg/ml. The serum and urine osmolarity were 239 and 371, respectively. Antidiure...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0256

    authors: Taskin M,Barker B,Calanog A,Jormark S

    更新日期:1996-09-01 00:00:00

  • Baboon cervical colposcopy, histology, and cytology.

    abstract::Colposcopic cervical/vaginal examinations were performed on 10 healthy adult baboons. Five of the ten baboons had a "satisfactory" colposcopic cervical examination with columnar epithelium visible on the exocervix. However, only three of five with "satisfactory" colposcopic exams had large visible transformation zones...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(84)90216-6

    authors: Micha JP,Quimby F

    更新日期:1984-03-01 00:00:00

  • Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer.

    abstract:OBJECTIVE:To investigate the neutrophil-to-lymphocyte ratio (NLR) from peripheral blood, a general measure of inflammation, in ovarian cancer. METHODS:White cell counts and CA125 levels before treatment, tumor features, and questionnaire data on 519 women with ovarian cancer at two Boston hospitals were recorded. Coun...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.01.026

    authors: Williams KA,Labidi-Galy SI,Terry KL,Vitonis AF,Welch WR,Goodman A,Cramer DW

    更新日期:2014-03-01 00:00:00

  • A pilot study of intra-arterial carboplatin in patients with recurrent carcinoma of the cervix, postradiation.

    abstract::Twelve patients with recurrent squamous cell carcinoma of the cervix restricted to the pelvis were treated with intra-arterial infusion of carboplatin. The initial carboplatin dose was 300 mg/m2, every 4 weeks, and the dose was escalated to 450 mg/m2. Myelosuppression was the dose-limiting toxicity at the 450 mg/m2 do...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1994.1136

    authors: Verma S,Prefontaine M,Bertrand M,Genest P,Dahrouge S

    更新日期:1994-06-01 00:00:00

  • Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

    abstract:OBJECTIVE:The AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC). METHODS:Nine hundred and forty patients with histologically confirmed AOC, International Federation of Gyneco...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ygyno.2019.08.024

    authors: Vergote I,du Bois A,Floquet A,Rau J,Kim JW,Del Campo JM,Friedlander M,Pignata S,Fujiwara K,Colombo N,Mirza MR,Monk BJ,Tsibulak I,Calvert PM,Herzog TJ,Hanker LC,Meunier J,Lee JY,Bologna A,Carrasco-Alfonso MJ,Harter

    更新日期:2019-11-01 00:00:00

  • Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma.

    abstract::Adriamycin (50 mg/m2) and cis-diamminedichloroplatinum (50 mg/m2) were administered every 21 days to treat metastatic endometrial adenocarcinoma. This regimen resulted in three responses (one complete and two partial) in nine women (33%). Most patients had moderate or severe hematologic and gastrointestinal toxicity. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(84)90197-5

    authors: Seltzer V,Vogl SE,Kaplan BH

    更新日期:1984-11-01 00:00:00

  • Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery.

    abstract:OBJECTIVE:Describing the pattern of and reasons for post-operative tumor residuals in patients with advanced epithelial ovarian cancer (AOC) operated in a specialized gynecologic cancer center following a strategy of maximum upfront debulking followed by systemic chemotherapy. METHODS:All consecutive AOC-patients trea...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2016.03.015

    authors: Heitz F,Harter P,Alesina PF,Walz MK,Lorenz D,Groeben H,Heikaus S,Fisseler-Eckhoff A,Schneider S,Ataseven B,Kurzeder C,Prader S,Beutel B,Traut A,du Bois A

    更新日期:2016-05-01 00:00:00

  • Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

    abstract:OBJECTIVE:Previous studies by the Gynecologic Oncology Group have demonstrated a 7% response rate with bolus etoposide as second-line therapy in nonsquamous cell carcinoma of the cervix. Prolonged oral etoposide, which exploits the schedule dependency of this agent, has demonstrated increased activity in squamous carci...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/s0090-8258(03)00079-9

    authors: Rose PG,Blessing JA,Buller RE,Mannel RS,Webster KD

    更新日期:2003-05-01 00:00:00

  • Endocrine therapy in endometrial cancer: An old dog with new tricks.

    abstract::One of the most prevalent potential therapeutic targets for women with endometrioid endometrial cancer (EC) is the estrogen receptor (ER)/progesterone receptor (PR) pathway. Despite a high proportion of endometrioid ECs being ER and/or PR positive, endocrine therapy is only effective in a minority of women with EC and...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2018.12.018

    authors: Jerzak KJ,Duska L,MacKay HJ

    更新日期:2019-04-01 00:00:00

  • Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study.

    abstract:OBJECTIVES:Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent carcinoma of the endometrium, and the combination of these two agents has shown activity in a variety of solid tumors. We administered this combination to patients with metastatic or recurrent carcinoma of the endom...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.2000.5827

    authors: Dimopoulos MA,Papadimitriou CA,Georgoulias V,Moulopoulos LA,Aravantinos G,Gika D,Karpathios S,Stamatelopoulos S

    更新日期:2000-07-01 00:00:00

  • A modified incision and technique for total retroperitoneal access and lymph node dissection.

    abstract::Surgical assessment of aortocaval lymph nodes in patients with unresectable primary cervical cancer helps in planning radiation treatment ports. Removal of enlarged lymph nodes may also serve a therapeutic purpose in reducing the tumor load to be sterilized by radiation. An extraperitoneal dissection is considered to ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1036

    authors: Vasilev SA

    更新日期:1995-02-01 00:00:00

  • Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.

    abstract:OBJECTIVES:Mature cystic teratoma of the ovary transforms into malignant tumors, mostly squamous cell carcinomas, at an incidence of approximately 2%. Preoperative diagnosis of squamous cell carcinoma arising in mature cystic teratoma of the ovary is a difficult task. The present study aims to assess whether combined u...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5784

    authors: Suzuki M,Tamura N,Kobayashi H,Ohwada M,Terao T,Sato I

    更新日期:2000-06-01 00:00:00

  • Retinoblastoma protein expression in endometrial hyperplasia and carcinoma.

    abstract::The retinoblastoma (RB) gene was the first defined tumor suppressor gene. While originally described in retinoblastoma, more recently alterations in RB have been described in a number of other human neoplasms and there has been a suggestion that alteration of RB may play a significant role in the development of endome...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4664

    authors: Niemann TH,Yilmaz AG,McGaughy VR,Vaccarello L

    更新日期:1997-05-01 00:00:00

  • Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.

    abstract:OBJECTIVE:To evaluate the efficacy and safety of involved-field radiation therapy (IFRT) in patients with locoregionally confined recurrent or persistent epithelial ovarian cancer. METHODS:This study included patients with recurrent epithelial ovarian cancer eligible for IFRT either during diagnosis of the recurrence ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2018.08.012

    authors: Chang JS,Kim SW,Kim YJ,Kim JY,Park SY,Kim JH,Jang TK,Kim YB

    更新日期:2018-10-01 00:00:00

  • Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor.

    abstract:OBJECTIVE:To investigate the tumorigenesis of mutant [12Asp]-K-ras in endometrial carcinoma and its relationship with ER. METHODS:We constructed pcDI-[12Asp]K-ras4B by inserting full-length [12Asp]K-ras4B from human endometrial carcinoma Hec-1A cells, into pcDI vector. Cell proliferation of NIH3T3 after transfection w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.10.016

    authors: Tu Z,Gui L,Wang J,Li X,Sun P,Wei L

    更新日期:2006-05-01 00:00:00

  • Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group.

    abstract:OBJECTIVES:The objective of this study was to determine whether ovarian preservation is feasible in younger endometrial cancer patients. METHODS:Endometrial cancer patients who underwent ovary-saving surgery were recruited from the tumor registries of 14 tertiary hospitals under the influence of the Korean Gynecologic...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.06.041

    authors: Lee TS,Kim JW,Kim TJ,Cho CH,Ryu SY,Ryu HS,Kim BG,Lee KH,Kim YM,Kang SB,Korean Gynecologic Oncology Group.

    更新日期:2009-10-01 00:00:00

  • Hospital-acquired conditions after surgery for gynecologic cancer - An analysis of 82,304 patients.

    abstract:OBJECTIVE:To evaluate the hospital-acquired condition (HAC) following oophorectomy and/or hysterectomy for gynecologic cancer patients based on clinical outcomes and costs. MATERIALS AND METHODS:Data were obtained from the Nationwide Inpatient Sample from 2005 to 2011. Chi-squared and Wilcoxon rank sum two-sample test...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.07.009

    authors: Chan JK,Gardner AB,Mann AK,Kapp DS

    更新日期:2018-09-01 00:00:00

  • Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).

    abstract:PURPOSE:To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. PATIENTS AND METHODS:We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (wee...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.10.031

    authors: Lee JY,Park JY,Park SY,Lee JW,Kim JW,Kim YB,Jeong DH,Lee KB,Kim TH,Lee IH,Choi MC,Kim KH,Kim YM,Lee YJ,Kang S,KGOG Investigators.,Pujade-Lauraine E

    更新日期:2019-01-01 00:00:00

  • Uterine tumors in ataxia-telangiectasia.

    abstract::Roughly one-third of patients with ataxia-telangiectasia (AT) develop malignant tumors, usually of lymphoid origin. AT patients also exhibit progeric changes. We describe three patients, between the ages of 27 and 32 years, with uterine tumors: one with a frank leiomyosarcoma and chronic T-cell leukemia, one with a mu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(89)80045-9

    authors: Gatti RA,Nieberg R,Boder E

    更新日期:1989-02-01 00:00:00

  • Conservative management in primary genital lymphomas: the role of chemotherapy.

    abstract:BACKGROUND:The female genital lymphomas are an extremely rare disease accounting for less than 0.5% of gynecological cancers and for 1.5% of all NHL. Because of their low incidence there is no widely accepted consensus on its treatment. Literature data support a radiotherapy-based treatment in case of primary genital l...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.08.024

    authors: Signorelli M,Maneo A,Cammarota S,Isimbaldi G,Garcia Parra R,Perego P,Maria Pogliani E,Mangioni C

    更新日期:2007-02-01 00:00:00

  • Treatment options for advanced endometrial carcinoma.

    abstract:OBJECTIVE:Endometrial carcinoma is the most common malignancy of the female reproductive tract. Most cases are diagnosed at an early stage due to the appearance of symptoms such as postmenopausal bleeding. However, endometrial carcinoma carries a poor prognosis when it recurs after previous definitive treatment or when...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2010.02.007

    authors: Dizon DS

    更新日期:2010-05-01 00:00:00

  • Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study.

    abstract:PURPOSE:To determine overall survival and progression-free survival among patients with high-risk, stage III and IV endometrial cancer who receive paclitaxel and carboplatin (TC) after complete tumor resection. PATIENTS AND METHODS:Patients with stage III/IV endometrial cancer with less than 2 cm of disease after surg...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.03.019

    authors: Sovak MA,Hensley ML,Dupont J,Ishill N,Alektiar KM,Abu-Rustum N,Barakat R,Chi DS,Sabbatini P,Spriggs DR,Aghajanian C

    更新日期:2006-11-01 00:00:00

  • Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.

    abstract:OBJECTIVES:SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7. This trial was designed to evaluate the efficacy and toxicities of HspE7 in women with CIN III. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2007.04.038

    authors: Einstein MH,Kadish AS,Burk RD,Kim MY,Wadler S,Streicher H,Goldberg GL,Runowicz CD

    更新日期:2007-09-01 00:00:00

  • High homogeneity of MMR deficiency in ovarian cancer.

    abstract:OBJECTIVE:Mismatch repair (MMR) deficiency and Bethesda panel microsatellite instability (MSI) are increasingly analyzed to identify tumors that might benefit from immune checkpoint inhibitors, but tumor heterogeneity is a potential obstacle for such analyses. In ovarian cancer, data on intratumoral heterogeneity of MM...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.12.031

    authors: Fraune C,Rosebrock J,Simon R,Hube-Magg C,Makrypidi-Fraune G,Kluth M,Büscheck F,Höflmayer D,Schmalfeldt B,Müller V,Wölber L,Witzel I,Paluchowski P,Wilke C,Heilenkötter U,von Leffern I,Clauditz TS,Wilczak W,Sauter G,S

    更新日期:2020-03-01 00:00:00

  • Angiomyofibroblastoma of the vulva.

    abstract::Angiomyofibroblastoma is a rare, myxoid tumor of the vulva. To date only 12 cases have been reported in the world literature. Patients are usually premenopausal and present with a vulval mass initially diagnosed as a Bartholin's cyst. The lesions are well circumscribed and range from 0.5 to 12 cm in size. Microscopica...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1994.1230

    authors: Van der Griend MD,Burda P,Ferrier AJ

    更新日期:1994-09-01 00:00:00

  • Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?

    abstract::Aggressive tumor reduction surgery has been widely used in patients with advanced stage epithelial ovarian carcinoma before initiation of cytotoxic chemotherapy. No randomized controlled trial has been carried out to confirm the benefits of such procedures. To examine the role of cytoreductive surgery in the managemen...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4839

    authors: Le T,Krepart GV,Lotocki RJ,Heywood MS

    更新日期:1997-11-01 00:00:00